跳至主要内容
临床试验/IRCT20180222038824N1
IRCT20180222038824N1已完成3 期

Comparison of the effectiveness and safety between Alpha chain Erythropoietin and Beta chain Erythropoietin produced by Iran in the Remodeling of Anemia in Children with Chronic kidney disease

Iran University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
3 months 至 18 years(—)
性别
All

入选标准

  • Parent consent for Research, Children With under 18 years old, children with hemoglobin less than 11 gr/dl, Renal failure with Grade 3-5 ,if that treatment with iron and folic acid and vitamin B12 have not modify the anemia,

排除标准

  • No consent of parents
  • Secondary anemia due to causes other than CKD
  • advanced liver disease
  • Uncontrolled hyperparathyroidism
  • Heart failure (New York Heart Association (NYHA) class III and IV)
  • Discoagulopathy
  • Thrombocytopenia
  • Acute or chronic bleeding during the last two month ago
  • Systemic or inflammatory infection
  • Major surgery during the last 6 months ago (except surgery for vessels access )
  • Immune suppressive treatment
  • History of malignancy
  • severe drug hypersensitivity
  • Every reception of blood during the last 3 months ago
  • Every primary blood disorder (Myelodysplasia syndrome, Myeloma, Sickle cell anemia, Malignancy, Multiple Myeloma)
  • Documented resistance to rHuEPO

研究者

相似试验